- Company
- The sales of Prolia & Evenity exceed ₩100 billion
- by Mar 10, 2022 05:53am
- Amgen has opened an era of 100 billion won in the osteoporosis treatment market. Sales of the two products are increasing rapidly as sequential treatments leading to Evenity-Prolia are being put forward. According to IQVIA, a pharmaceutical research institute, sales of Amgen's osteoporosis treatment, Denosumab, stood at 92.1 billion won last
- Company
- Why the Patent Court rejected the ‘prodrug strategy’
- by Kim, Jin-Gu Mar 10, 2022 05:53am
- Dong-A ST is challenging the substance patent of AstraZeneca’s SGLT-2 inhibitor antidiabetic treatment ‘Forxiga (dapagliflozin).’ The industry’s eyes are focused on Dong-A ST’s challenge, with the expectation that Dong-A ST’s success would bring a new strategy that can overcome the substance patent of originals. However, Dong-A
- Company
- Keytruda for esophageal cancer indications is imminent
- by Eo, Yun-Ho Mar 8, 2022 06:08am
- Keytruda, an immuno-cancer drug, is expected to be able to be prescribed for esophageal cancer. According to related industries, the MFDS has finally reviewed the first round of local progressive or metastatic esophageal cancer (GEJ), in which PD-1 inhibitory immuno-cancer drug Keytruda (Pembrolizumab) of MSD is non-resectable. Permission is
- Company
- Generation shift of ALK targeted drugs... rise of Alecensa
- by Mar 8, 2022 06:08am
- The targeted cancer therapy market for patients with ALK mutations has been restructured around second-generation drugs. The share of the first-generation drug Xalkori, which used to occupy 2/3 of the market fell to 20%, and the representative second-generation drug ‘Alecensa' took over the market. However, Alunbrig, a latecomer into the second
- Company
- Domestic production of Sputnik V was delayed
- by Kim, Jin-Gu Mar 8, 2022 06:08am
- Due to the war between Russia and Ukraine, shipments of domestic companies that consignment produce the COVID-19 vaccine Koruspharm developed by Russia are also being postponed indefinitely. Koruspharm said in a telephone interview with Dailypharm on the 4th, "We are continuously talking to the Russian side via e-mail or phone call even af
- Company
- Changes in the lung cancer treatment market are detected
- by Mar 7, 2022 05:50am
- Changes are detected in the EGFR targeted anticancer drug market, which Tagrisso dominated. Tagrisso sales stagnated for the first time due to sluggish primary treatment benefits. Leclaza, the only domestic new drug in the market, is threatening Tagrisso. According to IQVIA, a pharmaceutical research institute, on the 5th, the size of the dom
- Company
- Immuno-oncology drugs make ₩400 billion after 7 years
- by Mar 7, 2022 05:49am
- The immuno-oncology drug market exceeded &8361;400 billion in annual sales only 7 years since its debut in Korea. With Keytruda in the lead making over &8361;200 billion in sales, the latecomers Tecentriq and Imfinzi are chasing the lead with its rapid growth. According to the market research institution IQVIA on the 4th, the total imm
- Company
- Organon is focusing on expanding the women's health lineup
- by Mar 7, 2022 05:49am
- The demand for unmet diseases related to women's entire life cycle was relatively high. Organon will focus on improving treatment accessibility so that all women can enjoy healthier daily lives." At a press conference held by Organon for the first time since its launch at The Plaza Hotel in Jung-gu, Seoul on the morning of the 2nd, CEO Kim So-e
- Company
- First RSA drug ‘Erbitux’ to receive second reevaluations
- by Eo, Yun-Ho Mar 4, 2022 05:57am
- The term of risk-sharing agreements of major anticancer drugs are again nearing expiry. Starting with Merck’s ‘Erbitux (cetuximab), the first drug to be reimbursed with the RSA scheme in Korea, a series of other drugs are also awaiting reevaluations until 2023. According to industry sources, the colorectal cancer treatment Erbitux’s
- Company
- ↓↓Sales of smoking cessation txs by 75% in 4 yrs
- by Ji Yong Jun Mar 4, 2022 05:56am
- The market for Varenicline, a non-smoking supplement, has fallen to a quarter in four years. This is because the distribution of the original drug Pfizer Champix, which led the market, was suspended due to an impurity crisis in the second half of last year. According to IQVIA, a pharmaceutical research institute, sales of Varenicline last year
